Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good morning. And welcome to the Taysha Gene Therapies full year 2024. At this time, all participants are in a listen-only mode.
Taysha Gene Therapies Inc. (TSHA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 19,999,999 | $34,599,998 | +8% | 0.48% |
| 2. | RA Capital Management Peter Kolchinsky | 10,872,503 | $18,809,430 | 0.25% | |
| 3. | Octagon Capital Advisors Ting Jia | 10,450,000 | $18,078,500 | +129% | 2.97% |
| 4. | Siren L.L.C. Raymond Debbane | 6,602,475 | $11,422,282 | 0.5% | |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 5,000,000 | $8,650,000 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.25 | 1,333,333 | 1,333,333 | 2024-06-27 | Filing | ||
| $1.63 | 100,000 | Large Shareholder | 16,566,667 | 2023-11-17 | Filing | |
| $0.90 | 16,466,667 | Large Shareholder | 16,466,667 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | Director | 999,381 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | Director | 884,290 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.33 | 33,000 | Officer | 258,042 | 2023-08-24 | Filing | |
| $0.70 | 5,344 | 8,871,747 | 2023-07-13 | Filing | ||
| $0.71 | 80,528 | 8,877,091 | 2023-07-12 | Filing | ||
| $0.70 | 18,100 | Large Shareholder | 8,957,619 | 2023-06-23 | Filing | |
| $0.70 | 10,508 | Large Shareholder | 8,975,719 | 2023-06-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,640,366 | $30,517,834 | 0% | |
| 2. | 16,365,664 | $28,312,599 | 0% | |
| 3. | 13,531,467 | $23,409,438 | 0% | |
| 4. | 8,906,764 | $15,408,701 | 0% | |
| 5. | 8,672,630 | $15,003,650 | 0.22% |
News See All
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Call Transcript
Operator: Greetings. And welcome to the Taysha Gene Therapies’ Third Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
7 Best NASDAQ Stocks Under $5
A Yahoo Finance report on September 28 reveals that consumers are beginning to feel the effects of a cooling labor market, according to the latest Consumer Confidence Index, which shows a narrowing gap...
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2024 Earnings Call Transcript
Operator: Greetings and welcome to the Taysha Gene Therapies Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Is Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Taysha Gene Therapies, Inc.
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and understand the reasons behind...
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2024 Earnings Call Transcript
Operator: Greetings and welcome to the Taysha Gene Therapies First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript
Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $0.92, expectations were $-0.09.
5 Best Rising Penny Stocks To Buy
Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program.
Billionaire Hedge Funds
